Kay Decker
YOU?
Author Swipe
View article: CD47 Blockade Enhances Immunoradiotherapy Response in Head and Neck Squamous Cell Carcinoma
CD47 Blockade Enhances Immunoradiotherapy Response in Head and Neck Squamous Cell Carcinoma Open
Head and neck squamous cell carcinoma (HNSCC) is a significant cause of morbidity and mortality worldwide, with limited treatment options for patients with locally advanced disease. CD47 immune checkpoint inhibitors have been used to block…
View article: From Theory to Therapy: Evaluating Canadian Hemophilia Treatment Centres' Readiness for Gene Therapy Implementation
From Theory to Therapy: Evaluating Canadian Hemophilia Treatment Centres' Readiness for Gene Therapy Implementation Open
Introduction: Gene therapies (GT) present a transformative promise for persons with hemophilia, potentially offering a long-term solution to improve patient care and experiences. However, in publicly funded systems, GT's promise will fall …
View article: Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada
Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada Open
Introduction Damoctocog alfa pegol (BAY 94–9027, Jivi®) is an extended half‐life recombinant factor (F)VIII replacement, indicated for the treatment of haemophilia A in patients aged ≥12 years. Following introduction of damoctocog alfa peg…
View article: OC 24.4 Effect of F8 Mutations and Von Willebrand Factor on Pharmacokinetics of FVIII Concentrates in Severe Hemophilia A
OC 24.4 Effect of F8 Mutations and Von Willebrand Factor on Pharmacokinetics of FVIII Concentrates in Severe Hemophilia A Open
bleeds in life, 10 (4%) with at least a spontaneous joint bleed.The mean annualized joint bleeding rate (AJBR) and spontaneous AJBR were 0.0155 [standard deviation (SD): 0.0317] and 0.0014 (SD: 0.0097), respectively.Lower mean FVIII levels…
View article: Comparison of perioperative practices for placement of central venous access devices (CVAD) in children with haemophilia
Comparison of perioperative practices for placement of central venous access devices (CVAD) in children with haemophilia Open
Background In children with haemophilia (CwH), central venous access devices (CVADs) are frequently placed to aid in the delivery of factor concentrates. In those who develop inhibitors, CVADs also allow for easy venous access and facilita…
View article: Development of decision-making considerations to support equitable patient selection in paediatric haemophilia trials
Development of decision-making considerations to support equitable patient selection in paediatric haemophilia trials Open
Background Clinical trials for investigational haemophilia treatments such as gene therapy offer a potentially life-changing opportunity to those who are selected for enrolment. However, the number of enrolment slots available for these tr…
View article: Telemedicine in haemophilia during COVID-19 and beyond: a comprehensive review
Telemedicine in haemophilia during COVID-19 and beyond: a comprehensive review Open
Introduction Patients with haemophilia require regular assessments and physical examinations. The COVID-19 pandemic has resulted in the rapid adoption of telemedicine to enable virtual consultations and reduce hospital visits. However, the…
View article: Web-based Application for the Population Pharmacokinetic Service (WAPPS)'s impact on dosage selection: a single paediatric centre experience
Web-based Application for the Population Pharmacokinetic Service (WAPPS)'s impact on dosage selection: a single paediatric centre experience Open
Background Current treatment for severe haemophilia includes prophylactic factor replacement to prevent bleeding. Coagulation factor products have significant inter-patient variability in pharmacokinetic (PK) parameters. Optimal management…